Not finding it? Sign in to also search OpenAlex live.
-
Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Richard Kelly, Austin Gladston Kulasekararaj, Alexander Röth, Phillip Scheinberg, Yasutaka Ueda, +4 more
0citations -
Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Juan Carlos Vallejo Llamas, Koo Wilson, Zalmaï Hakimi, Barbara Czech, Sam Williamson, +4 more
1citations -
Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, +10 more
0citations -
MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size With Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients2023 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Bing Han, Jaroslaw Pawel Maciejewski, Yasutaka Ueda, Rong Fu, Li Zhang, +15 more
1citations -
ABS0517 LONG-TERM SAFETY AND EFFICACY OF THE COMBINATION OF BELIMUMAB AND RITUXIMAB IN THE TREATMENT OF SEVERE AND REFRACTORY SLE: A PRELIMINARY REPORT2025 Annals of the Rheumatic Diseases conference-abstract Medicine Systemic Lupus Erythematosus Research Open access
Mieke van Schaik, E. Arends, Marjolein J.A.L. Wetzels, Sylvia W.A. Kamerling, Tom W. J. Huizinga, Robbert J Goekoop, +2 more
0citations -
LB1529. Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab's Effect on Mortality in Critically Ill COVID-19 Patients: A Therapy for Viral Pneumonia2022 Open Forum Infectious Diseases conference-abstract Medicine COVID-19 Clinical Research Studies Open access cited by 3 patents
Bruno Mourvillier, Alexander P. J. Vlaar, Martin Witzenrath, Michael W Bauer, Leo M. A. Heunks, Luis Hercilla Vásquez, +23 more
0citations -
Single-Cell Transcriptomics Indicate That CD163+ Kidney Macrophages Are Pro-Inflammatory and May Orchestrate Further Immune Cell Recruitment to Kidney Lesions in ANCA-Associated Glomerulonephritis2022 Journal of the American Society of Nephrology conference-abstract Medicine Vasculitis and related conditions
Yosta Vegting, Aldo Jongejan, Ester B. M. Remmerswaal, Perry D. Moerland, Jesper Kers, Liffert Vogt, +2 more
0citations -
PB0121 Relationship of Thrombo-Inflammatory Biomarkers with Oxidative Stress Level in Non-Small Cell Lung Cancer Patients2023 Research and Practice in Thrombosis and Haemostasis conference-abstract Medicine Blood Coagulation and Thrombosis Mechanisms Open access
Srdjan S. Nikolovski, Mark Jaradeh, Jeanine M. Walenga, D. Hoppensteadt, Bülent Kantarcıoğlu, Jawed Fareed, +1 more
1citations -
Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study
Martin Witzenrath, Alexander P.J. Vlaar, Michael W Bauer, Djillai Annane, L.M.A. Heunks, Bruno Mourvillier, +26 more
2citations -
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, +4 more
4citations -
Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, J Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
2citations -
The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Anna Gayà, Morag Griffin, Bing Han, Austin Gladston Kulasekararaj, Jaroslaw Pawel Maciejewski, +11 more
0citations -
Thrombosis and Encapsulated Bacterial Infection Rates in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Pegcetacoplan: Nearly 3 Years of Post-Marketing Experience2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Gloria Frances Gerber, Richard Kelly, Hisakazu Nishimori, Regina Horneff, Peter Hillmen, Uchendu Orizu Uchendu, +2 more
1citations -
Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from Phase 2 studies who entered the roll-over extension program
Antonio Maria Risitano, Camilla Frieri, Bor‐Sheng Ko, Lily Wong Lee Lee, Alexander Röth, Flore Sicre de Fontbrune, +8 more
0citations -
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
Antonio Maria Risitano, Austin Gladston Kulasekararaj, Alexander Roeth, Phillip Scheinberg, Yutaka Ueda, Eros Di Bona, +29 more
14citations -
Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Koo Wilson, Sam Williamson, Susanna Libby, Peter Hillmen, David Dingli
0citations -
Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, Jun‐ichi Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
0citations -
MDS-112 Normalization of Hematologic and Health-Related Quality of Life Markers in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Pegcetacoplan and Baseline Hemoglobin at or Above 10 g/dL2022 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases
Dharmik Desai, Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, +5 more
1citations -
MDS-1159: Long-Term Safety With Iptacopan Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Pooled Analysis of Data From Phase 2 and 3 Studies and the Roll-Over Extension Program2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases
Alexander Röth, Austin Gladston Kulasekararaj, Camilla Frieri, Flore Sicre de Fontbrune, Phillip Scheinberg, Bor‐Sheng Ko, +8 more
0citations -
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Phillip Scheinberg, Diego V. Clé, Bérangère Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan‐Yu Lin, +12 more
0citations -
Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter2021 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +5 more
1citations -
Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials
Antonio Maria Risitano, Bing Han, Austin Gladston Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Jaroslaw Pawel Maciejewski, +7 more
2citations